Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.

Research Grants 140 show all


$7.3M
2010

$1.2M
2011

$1.1M
2012

$225K
2016

$563.8K
2018

Patents 303show all

  • 112
    A61K - Preparations for medical, dental, or toilet purposes
  • 70
    C07K - Peptides
  • 23
    C12N - Microorganisms or enzymes
  • 21
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 15
    F16L - Pipes
  • 11
    A01K - Animal husbandry
  • 9
    C07D - Heterocyclic compounds
  • 6
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 5
    A61Q - Specific use of cosmetics or similar toilet preparations
  • 5
    B29C - Shaping or joining of plastics

Clinical Trials 56show all

17Phase 215Phase 110Phase 33N/A3Phase 2/Phase 33Phase 43Other

SEC Filings show all


356
8-K

67
10-Q

22
10-K

2
D

1
S-1

Contact Information

777 Old Saw Mill River Road
Tarrytown, NY 10591
United States

Overview

Total FundingEmployeesLast Funding DateStatus
51-100Acquired

SEC Form D Funding Events

DateOfferedSoldType
2013-01-28Indefinite$12,922,374Equity
2006-01-04Unknown Unknown Other (Paper Filing)

Key Executives

  • Mark R. Baker
    Executive Officer, Director
  • Robert J. Israel
    Executive Officer
  • William C. Olson
    Executive Officer
  • Peter J. Crowley
    Director
  • Paul J. Maddon
    Director
  • Charles A. Baker
    Director
  • Kurt W. Briner
    Director
  • Stephen P. Goff
    Director
  • David A. Scheinberg
    Director
  • Nicole S. Williams
    Director